홈MCP워크벤치Skills
홈워크벤치알림마이페이지
Huagongshe 오픈 프로젝트:[email protected]AI 접속: llms.txt · MCP 가이드개인정보처리방침 · 이용약관 · 지원v1.7.8
  1. 홈
  2. /화합물

타조박탐산

Tazobactam

HCID 123630
노트반응
기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트
부분 구조 검색유사 구조 찾기

기본 정보

CAS
89786-04-9
표준 SMILES
C[C@]1(Cn2ccnn2)[C@H](C(=O)O)N2C(=O)C[C@H]2S1(=O)=O
InChIKey
LPQZKKCYTLCDGQ-WEDXCCLWSA-N
분자식
C10H12N4O5S
평균 분자량
300.29 g/mol
단동위원소 질량
300.05284067

개요

Tazobactam is a member of the class of penicillanic acids that is sulbactam in which one of the exocyclic methyl hydrogens is replaced by a 1,2,3-triazol-1-yl group; used (in the form of its sodium salt) in combination with ceftolozane sulfate for treatment of complicated intra-abdominal infections and complicated urinary tract infections. It has a role as an antimicrobial agent, an antiinfective agent and an EC 3.5.2.6 (beta-lactamase) inhibitor. It is a member of penicillanic acids and a member of triazoles. It is functionally related to a sulbactam. It is a conjugate acid of a tazobactam(1-).

이름 및 식별자

우선 이름
Tazobactam
IUPAC
(2S,3S,5R)-3-methyl-4,4,7-trioxo-3-(triazol-1-ylmethyl)-4λ6-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
현지명
타조박탐산
영어명
Tazobactam acid
분자식
C10H12N4O5S
분자량
300.29

이름 및 동의어

Tazobactam89786-04-9TazobactamumYTR-830HCL 298,741CHEBI:9421SE10G96M8WNSC-759887CXA201YTR830DTXSID8023634(2S,3S,5R)-3-Methyl-7-oxo-3-(1H-1,2,3-triazol-1-ylmethyl)-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 4,4-dioxide
이름 더 보기
타조박탐산Tarobactam acidytr83ohcl2987417-Methyl-2H-1Tazobactam RSHe (the templeTAZOBACTAM USP
4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 3-methyl-7-oxo-3-(1H-1,2,3-triazol-1-ylmethyl)-, 4,4-dioxide, (2S,3S,5R)-(2S,3S,5R)-3-methyl-4,4,7-trioxo-3-(1H-1,2,3-triazol-1-ylmethyl)-4$l^(6)-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid(2S,3S,5R)-3-methyl-4,4,7-trioxo-3-(1H-1,2,3-triazol-1-ylmethyl)-4$l^{6}-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 3-methyl-7-oxo-3-(1H-1,2,3-triazol-1-ylmethyl)-, 4,4-dioxide, (2S,3S,5R)-RefChem:891206DTXCID003634J01CG02YTR-830

데이터베이스 식별자

CAS
89786-04-9

물성

구조 계산 물성

XLogP
-2
극성 표면적
131 Ų
수소 결합 공여자 수
1
수소 결합 수용자 수
7
회전 가능 결합 수
3
무거운 원자 수
20
형식 전하
0
복잡도
573

실험 및 물리화학적 성질

Drugs · 4건

Pharmaceuticals -> Antibiotics

Pharmaceuticals -> Listed in ZINC15

Pharmaceuticals -> Antibiotics

Pharmaceuticals -> Used in Switzerland

Solubility9.59e+00 g/L
Melting Point140-147
Physical DescriptionSolid
Dissociation Constants2.1
Collision Cross Section157.7 Ų [M-H]- [CCS Type: DT; Buffer gas: N2; Ionization: ESI-; Dataset: TOXCAST; Source Identifier: DTXSID8046030]

물리화학적 성질

녹는점
115 · 115-145℃
끓는 점
77 ℃ · 77℃
밀도
1.92 · 1.92±0.1 g/cm3(Predicted)
인화점
110 ° · >110°(230°F)
저장 조건
-20 °C · Sealed in dry,Store in freezer, under -20°C
용해도
DMSO(약간 가열), 메탄올(약간 가열, 초음파 처리)에 용해됨
물리적 상태
Solid

안전 및 규제

안전 정보는 참고용이며, 공급업체의 물질안전보건자료(SDS), 관련 법규 및 전문가 평가를 대체하지 않습니다.

GHS 분류

GHS Classification · 4건

Danger

H317 (14.3%): May cause an allergic skin reaction [Warning Sensitization, Skin]

P233, P260, P261, P271, P272, P273, P280, P284, P302+P352, P304+P340, P319, P321, P333+P317, P342+P316, P362+P364, P391, P403, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 42 reports by companies from 3 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

유해성 정보

Regulatory InformationREACH registered substance: (2S,3S,5R)-3-methyl-7-oxo-3-(1H-1,2,3-triazol-1-ylmethyl)-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid 4,4-dioxide (EC: 618-303-7)
Hazard Classes and CategoriesSkin Sens. 1 (14.3%)

독성 정보

Drug Induced Liver Injury · 5건

Drug-Induced Liver Injury Severity and Toxicity (DILIst)

Tazobactam

DILI Negative

Intravenous; Parenteral

DOI:10.1016/j.drudis.2019.09.022

안전 데이터

wgk
3
HS 번호
2941106000
risk_code
36/37/38
hazard_code
Xi
safety_code
26-36

화학 및 산업

약리 정보

ATC Code · 2건

J - Antiinfectives for systemic use

QJ - Antiinfectives for systemic use

Protein BindingTazobactam is bout 30% bound to plasma proteins.
Pharmacodynamics · 1건

Tazobactam inhibits the action of bacterial beta-lactamase producing organisms, which are normally resistant to beta-lactam antibiotics. This augments the effects of antibiotics which would otherwise not be effective in treating certain infections. These antibiotics contain a beta-lactam ring in their chemical structure, which is destroyed by beta-lactam resistant organisms. When combined with other antibiotics, a variety of infections, including serious and life-threatening infections may be treated.

Mechanism of Action · 1건

Tazobactam broadens the spectrum of piperacillin and ceftolozane by making them effective against organisms that express beta-lactamase and would normally degrade them. This occurs through the irreversible inhibition of beta-lactamase enzymes. In addition, tazobactam may bind covalently to plasmid-mediated and chromosome-mediated beta-lactamase enzymes. Tazobactam is predominantly effective against the OHIO-1, SHV-1, and TEM groups of beta-lactamases, but may also inhibit other beta-lactamases. Tazobactam shows little antibacterial activity by itself, and for this reason, is generally not administered alone.

Biological Half-LifePiperacillin-tazobactam After a single dose in healthy volunteers, the plasma half-life of piperacillin and tazobactam was in the range of 0.7 to 1.2 hours. Ceftolozane-tazobactam 0.91-1.03 hours
Metabolism/MetabolitesTazobactam is mainly metabolized to M1, an inactive metabolite. Hydrolysis occurs on the beta-lactam ring to form M1 (the inactive metabolite).
FDA Pharmacological Classification · 5건

SE10G96M8W

TAZOBACTAM

Established Pharmacologic Class [EPC] - beta Lactamase Inhibitor

Mechanisms of Action [MoA] - beta Lactamase Inhibitors

관련 반응

17건
반응 기록 만들기
HRID 445909 반응식
HRID 445909반응물로uspto-grants-2013_07
HRID 445910 반응식
HRID 445910반응물로uspto-grants-2013_07
HRID 445911 반응식
HRID 445911반응물로uspto-grants-2013_07
HRID 445912 반응식
HRID 445912반응물로uspto-grants-2013_07
HRID 445913 반응식
HRID 445913반응물로uspto-grants-2013_07
HRID 445914 반응식
HRID 445914반응물로uspto-grants-2013_07
HRID 868757 반응식
HRID 868757생성물로반응물로uspto-grants-2015_03
HRID 868758 반응식
HRID 868758반응물로uspto-grants-2015_03
1 / 3 페이지

화합물 노트

불러오는 중…

이 페이지에서기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트
PubChem CID
123630
DTXSID
DTXSID8023634
ChEMBL
CHEMBL404
ChEBI
CHEBI:9421
UNII
SE10G96M8W
EC Number
618-303-7
산도 계수 (pKa)
2.33 · 2.33±0.40(Predicted)
색상
흰색에서 황백색까지
수용성
물에 용해됨
안정성
감광성
InChI
InChI=1S/C10H12N4O5S/c1-10(5-13-3-2-11-12-13)8(9(16)17)14-6(15)4-7(14)20(10,18)19/h2-3,7-8H,4-5H2,1H3,(H,16,17)/t7-,8+,10+/m1/s1
InChIKey
LPQZKKCYTLCDGQ-WEDXCCLWSA-N
SMILES
N12[C@@]([H])(CC1=O)S(=O)(=O)[C@@](C)(CN1C=CN=N1)[C@@H]2C(O)=O

화학적 성질

White or off-white powder

Tazobactam is a beta Lactamase Inhibitor. The mechanism of action of tazobactam is as a beta Lactamase Inhibitor.

MeSH Pharmacological Classification · 2건

Substances that inhibit the growth or reproduction of BACTERIA.

Endogenous substances and drugs that inhibit or block the activity of BETA-LACTAMASES.

Absorption, Distribution and Excretion · 4건

Tazobactam is coadministered with piperacillin or ceftolozane, pharmacokinetic information will be provided for these combinations. **Piperacillin-tazobactam** Peak plasma concentrations occur immediately after the completion of intravenous infusion. Following several doses of piperacillin-tazobactam infusions every 6 hours, peak concentrations were similar to those that were measured after the initial dose. **Ceftolozane-piperacillin** AUC: 24.4-25 mcg•h/mL Peak concentrations are reached on day 1 after the first dose and range from 18 to 18.4 mcg/mL.

Tazobactam and its metabolite are mainly eliminated by the kidneys with about 80% of the administered dose eliminated as unchanged drug. The remaining drug is excreted as a single metabolite.

18.2 L when given with piperacillin 13.5-18.2 L when given with ceftolozane Piperacillin-tazobactam is widely distributed in body tissues and fluids. These may include but are not limited to the intestine, gallbladder, lung, female reproductive organs, and the bile. Meningeal distribution of piperacillin-tazobactam increases with inflammation, but is otherwise low.

Because tazobactam is cleared by the kidneys and is a substrate of the transporters OAT1 and OAT3, inhibitors of these transporters should be avoided to ensure efficacy. Dosage adjustments of piperacillin-tazobactam and ceftolozane-tazobactam must be made for patients with impaired renal clearance. The mean clearance rate of tazobactam was found to be 48.3-83.6 mL/min in patients admitted to the intensive care unit who were given renal replacement therapy and receiving intravenous piperacillin-tazobactam. The clearance of tazobactam is dependent on renal function, as determined by renal clearance.

Cellular LocationsCytoplasm

용도 및 제조

UsesUse (kg) in Switzerland (2009): >100
응용 분야 · 2건

개요Tazobactam often is coadministered with piperacillin because of tazobactam's ability to inhibit β-lactamases. T azobactam, like other β-lactamase inhibitors, has little or no antibacterial activity. This effect is analogous to that of clavulanic acid and sulbactam.

용도b-lactamase inhibitor

상·하류 제품 정보

상류 원료

Sulbactam소디움 아지이드에틸알코올브로민화 칼륨요오드화 칼륨타조박탐나트륨과산화아세트산3-아미노-5-머캅토-1,2,4-트리아졸과망간산칼륨초산비닐모노머phenylhydrazone아세트산 암모늄규조토

공급사100 곳

国药集团化学试剂有限公司86-21-63210123 · [email protected]
北京华美互利生物化工010-56205725 · [email protected]
梯希爱(上海)化成工业发展有限公司021-67121386 · [email protected]
济南百隆化学有限公司[email protected] · [email protected]
合肥翰刚医药科技有限公司+8618062405514 · [email protected]
广州隽沐生物科技股份有限公司020-36607679; 13502246435 · [email protected]
武汉创硕化工科技有限公司180-62205282 18062205282 · [email protected]
河北展药生物科技有限公司15369953316 +8615369953316 · [email protected]
Baoji Guokang Healthchem co.,ltd+8615604608665 15604608665 · [email protected]
Hebei Henghe Import and Export Trading Co. LTD+8618032935937 18032916000 · [email protected]
南京望知星医药科技有限公司18569809817 · [email protected]
LGM Pharma1-(800)-881-8210 · [email protected]
上海晶抗生物工程有限公司021-54721350 13524668266 · [email protected]
大连美仑生物技术有限公司0411-62910999 13889544652 · [email protected]
太原市瑞和丰科贸有限公司+86 351 7031519 · [email protected]
Cangzhou Wanyou New Material Technology Co.,Ltd18631714998 · [email protected]
Pure Chemistry Scientific Inc.001-857-928-2050 or 1-888-588-9418 · [email protected]
上海泰坦科技股份有限公司4006009262 13023226327 · [email protected]
MedChemexpress LLC021-58955995 · [email protected]
武汉丰泰威远科技有限公司+86-27-8746-5837 +86-18627785180 · [email protected]
Zhejiang J&C Biological Technology Co.,Limited+1-2135480471 · [email protected]
上海瀚香生物科技有限公司177-54423994 17754423994 · [email protected]
合肥天健化工有限公司551-65418679 15856988503;15837135945 · [email protected]
武汉丰泰威远科技有限公司027-87465837 19945049750 · [email protected]
孝感深远化工有限公司15527621225; 15527621225 · [email protected]
云南西力生物技术股份有限公司0871-65217109 · [email protected]
HONG KONG IPURE BIOLOGY CO.,LIMITED86 18062405514 18062405514 · [email protected]
上海源叶生物科技有限公司18916372613 · [email protected]
TOKYO CHEMICAL INDUSTRY CO., LTD.03-36680489 · [email protected]
深圳振强药物研发有限公司0755-66853366 13670046396 · [email protected]
深圳康特腾科技有限公司86-0755-86635001 · [email protected]
南京生利德生物科技有限公司025-57798810 18652991625 · [email protected]
湖北威德利化学试剂有限公司186-02735115 18602735115 · [email protected]
成都零六生物科技有限公司400-1166-196 13458535857 · [email protected]
上海永叶生物科技有限公司86-021-61559134 15921386130 · [email protected]
陕西缔都医药化工有限公司+86-29-87569262 +86-15003564040 · [email protected]
上海孚一生物科技有限公司+86 (21) 61124340
南京熙泽医药科技有限公司025-66023220 15250997978 · [email protected]
TargetMol中国(陶术生物)021-021-33632979 15002134094 · [email protected]
上海陶术生物科技股份有限公司+1-781-999-5354; +1-00000000000 · [email protected]
湖北威德利化学科技有限公司027-83989310 18627915365 · [email protected]
湖北威德利化学试剂有限公司18327179646 · [email protected]
西安天广源生物科技有限公司+86-029-86333380 +86-18829239519 · [email protected]
浙江海强化工有限公司0571-86050367 0571-86960370 0571-86050387 · [email protected]
EMMX Biotechnology LLC888-539-0666 · [email protected]
上海诺吉化工科技有限公司021-021-61075308 15216782696 · [email protected]
上海炎泽化工有限公司15345144255 19901447308 · [email protected]
广州市齐云生物技术有限公司020-61288194 61288195 · [email protected]
上海前衍生物科技有限公司02781293128 · [email protected]
南京博米尔生物科技有限公司025-83453382-8005 · [email protected]
추가 설명 · 1건

정의ChEBI: A member of the class of penicillanic acids that is sulbactam in which one of the exocyclic methyl hydrogens is replaced by a 1,2,3-triazol-1-yl group; used (in the form of its sodium salt) in combination with ceftolozane sulfate for treatment of complicat d intra-abdominal infections and complicated urinary tract infections.